MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
2017 · Cancer Cell · 591 citations
https://doi.org/10.1016/j.ccell.2016.12.005
J
Johannes Brägelmann
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
195
Papers
4.4K
Citations
29
h-index
49
i10-index
Johannes Brägelmann is an academic researcher from University of Cologne. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & RNA modifications and cancer & Head and Neck Cancer Studies. The author has an h-index of 29, co-authored 166 publications.
ORCID: 0000-0002-1306-2169Papers by this author
worksElevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation
2022 · Cell Death and Differentiation · 116 citations
https://doi.org/10.1038/s41418-022-01096-8
RON<i>(MST1R)</i>is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
2011 · Cancer Biology & Therapy · 103 citations
https://doi.org/10.4161/cbt.12.1.15747
Functional synapses between neurons and small cell lung cancer
2025 · Nature · 21 citations
https://doi.org/10.1038/s41586-025-09434-9
ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer
2025 · Nature Communications · 3 citations
https://doi.org/10.1038/s41467-025-66800-x
Explainable, federated deep learning model predicts disease progression risk of cutaneous squamous cell carcinoma
2025 · npj Precision Oncology · 2 citations
https://doi.org/10.1038/s41698-025-00997-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat